Professor Richard Sullivan

Charles M Balch, Ning Liao, Dennis S C Lam, Jeffrey N Weitzel, Rui-Hua Xu, Gerhardt Attard, Paul A Bunn, Alexander M M Eggermont, Jie He, Yuko Kitagawa, Soon Thye Lim, Eduardo Cazap, Bernard Esquivel, Xianqun Fan, Louis W C Chow, Edward S F Liu, Hector Martinez Said, John E Niederhuber, Isabel T Rubio, Ashraf Saad Zaghloul, Oscar G Arrieta, Riccardo A Audisio, Geerard L Beets, Felipe J F Coimbra, Jorge E Gallardo, Judy E Garber, Alessandro Gronchi, Volker Heinemann, Allison W Kurian, Miriam...

Cancer is now a major cause of premature mortality in every region,1,2 yet the global health system still cannot answer basic questions about access to essential cancer medicines. Spending on oncology medicines reached US$223 billion in 2023,3 but there is no global mechanism that monitors whether these medications are available, affordable, or used appropriately. This absence of routine metrics has become a structural barrier to planning and accountability.

Susan Msadabwe, Peng Yun Ng, Richard Sullivan, Kennedy Lishimpi, John Kachimba, Justor Banda, Jane Mumba, Abidan Chansa, Mutuna Chiwele, Kasonde Bowa, Kaseya Chiyenu, Linda Malulu-Chiwele, Julie Torode, Grant Lewison, Andrew Leather, Ajay Aggarwal, Kathleen Schmeler, Groesbeck Parham, Kabisa Mwala, Paul Kamfwa Background: Zambia faces the double burden of rising cancer incidence and a disproportionate volume of mortality from delayed presentations.